AAPL346.47-1.76 (-0.50%) ▼|ABBV286.27+1.08 (+0.38%) ▲|ABT103.39+0.88 (+0.85%) ▲|ACN246.85-11.89 (-4.60%) ▼|ADBE265.46-5.09 (-1.88%) ▼|AMAT379.68+4.10 (+1.09%) ▲|AMD517.55+9.62 (+1.89%) ▲|AMGN440.79-6.50 (-1.45%) ▼|AMT188.31+6.74 (+3.71%) ▲|AMZN248.72-1.66 (-0.66%) ▼|AVGO324.44+1.20 (+0.37%) ▲|AXP313.19-11.99 (-3.69%) ▼|BA188.39+0.84 (+0.45%) ▲|BAC50.69-0.39 (-0.76%) ▼|BKNG157.14-3.96 (-2.46%) ▼|BLK1,113.83-23.46 (-2.06%) ▼|BMY61.60-1.41 (-2.23%) ▼|BNY145.18-0.14 (-0.10%) ▼|BRK-B541.26-5.72 (-1.04%) ▼|C120.98-1.53 (-1.25%) ▼|CAT687.03-17.02 (-2.42%) ▼|CL93.96-3.44 (-3.53%) ▼|CMCSA22.79-0.06 (-0.24%) ▼|COF200.41-3.03 (-1.49%) ▼|COP151.55+5.92 (+4.06%) ▲|COST1,005.69-12.53 (-1.23%) ▼|CRM248.53-1.76 (-0.70%) ▼|CSCO106.27+1.38 (+1.31%) ▲|CVS93.49-0.99 (-1.05%) ▼|CVX232.73+6.05 (+2.67%) ▲|DE644.45+0.83 (+0.13%) ▲|DHR227.11-2.64 (-1.15%) ▼|DIS112.83-0.30 (-0.27%) ▼|DUK124.62-0.78 (-0.62%) ▼|EMR162.15+1.86 (+1.16%) ▲|FDX299.08-4.84 (-1.59%) ▼|GD350.40-0.39 (-0.11%) ▼|GE287.94-5.60 (-1.91%) ▼|GEV825.89-1.53 (-0.18%) ▼|GILD156.61-0.58 (-0.37%) ▼|GM75.84-1.38 (-1.78%) ▼|GOOG319.00-1.76 (-0.55%) ▼|GOOGL322.04-2.18 (-0.67%) ▼|GS882.67-8.63 (-0.97%) ▼|HD318.43-9.30 (-2.84%) ▼|HON221.41+3.10 (+1.42%) ▲|IBM252.93+0.82 (+0.33%) ▲|INTC86.84+1.35 (+1.57%) ▲|INTU346.15-8.75 (-2.47%) ▼|ISRG453.48+9.63 (+2.17%) ▲|JNJ263.03-4.59 (-1.71%) ▼|JPM332.14-4.41 (-1.31%) ▼|KO92.81-2.54 (-2.66%) ▼|LIN508.28-2.08 (-0.41%) ▼|LLY1,264.74-41.96 (-3.21%) ▼|LMT606.54+16.63 (+2.82%) ▲|LOW198.74-5.63 (-2.75%) ▼|LRCX230.80+0.65 (+0.28%) ▲|MA622.06-11.15 (-1.76%) ▼|MCD247.61-5.02 (-1.99%) ▼|MDLZ63.54-1.65 (-2.53%) ▼|MDT95.87-0.72 (-0.75%) ▼|META644.58-4.28 (-0.66%) ▼|MMM173.96-1.61 (-0.91%) ▼|MO74.46-1.61 (-2.12%) ▼|MRK145.00-2.24 (-1.52%) ▼|MS180.85-3.12 (-1.70%) ▼|MSFT524.59+3.51 (+0.67%) ▲|MU883.15+26.66 (+3.11%) ▲|NEE81.71-0.19 (-0.23%) ▼|NFLX66.12-0.93 (-1.39%) ▼|NKE37.48-0.85 (-2.21%) ▼|NOW158.45+1.45 (+0.92%) ▲|NVDA211.67-0.54 (-0.25%) ▼|ORCL127.74+2.20 (+1.75%) ▲|PEP135.50-3.34 (-2.40%) ▼|PFE30.04-0.38 (-1.25%) ▼|PG161.31-3.19 (-1.94%) ▼|PLTR196.12-0.08 (-0.04%) ▼|PM199.53-2.21 (-1.10%) ▼|QCOM174.94+2.11 (+1.22%) ▲|RTX191.65-3.07 (-1.57%) ▼|SBUX100.70-1.21 (-1.19%) ▼|SCHW90.45-0.99 (-1.08%) ▼|SO92.91-0.92 (-0.98%) ▼|SPG210.98-1.06 (-0.50%) ▼|T21.23-1.52 (-6.66%) ▼|TMO670.40-6.14 (-0.91%) ▼|TMUS148.89-9.90 (-6.23%) ▼|TSLA372.06-2.52 (-0.67%) ▼|TXN284.60+5.10 (+1.82%) ▲|UBER67.21-1.87 (-2.70%) ▼|UNH417.92-7.07 (-1.66%) ▼|UNP294.02-4.07 (-1.37%) ▼|UPS101.29-0.23 (-0.23%) ▼|USB59.61-0.41 (-0.68%) ▼|V409.13-5.21 (-1.26%) ▼|VZ44.46-0.74 (-1.64%) ▼|WFC82.36-0.66 (-0.79%) ▼|WMT119.41-1.71 (-1.41%) ▼|XOM182.62+4.39 (+2.46%) ▲|AAPL346.47-1.76 (-0.50%) ▼|ABBV286.27+1.08 (+0.38%) ▲|ABT103.39+0.88 (+0.85%) ▲|ACN246.85-11.89 (-4.60%) ▼|ADBE265.46-5.09 (-1.88%) ▼|AMAT379.68+4.10 (+1.09%) ▲|AMD517.55+9.62 (+1.89%) ▲|AMGN440.79-6.50 (-1.45%) ▼|AMT188.31+6.74 (+3.71%) ▲|AMZN248.72-1.66 (-0.66%) ▼|AVGO324.44+1.20 (+0.37%) ▲|AXP313.19-11.99 (-3.69%) ▼|BA188.39+0.84 (+0.45%) ▲|BAC50.69-0.39 (-0.76%) ▼|BKNG157.14-3.96 (-2.46%) ▼|BLK1,113.83-23.46 (-2.06%) ▼|BMY61.60-1.41 (-2.23%) ▼|BNY145.18-0.14 (-0.10%) ▼|BRK-B541.26-5.72 (-1.04%) ▼|C120.98-1.53 (-1.25%) ▼|CAT687.03-17.02 (-2.42%) ▼|CL93.96-3.44 (-3.53%) ▼|CMCSA22.79-0.06 (-0.24%) ▼|COF200.41-3.03 (-1.49%) ▼|COP151.55+5.92 (+4.06%) ▲|COST1,005.69-12.53 (-1.23%) ▼|CRM248.53-1.76 (-0.70%) ▼|CSCO106.27+1.38 (+1.31%) ▲|CVS93.49-0.99 (-1.05%) ▼|CVX232.73+6.05 (+2.67%) ▲|DE644.45+0.83 (+0.13%) ▲|DHR227.11-2.64 (-1.15%) ▼|DIS112.83-0.30 (-0.27%) ▼|DUK124.62-0.78 (-0.62%) ▼|EMR162.15+1.86 (+1.16%) ▲|FDX299.08-4.84 (-1.59%) ▼|GD350.40-0.39 (-0.11%) ▼|GE287.94-5.60 (-1.91%) ▼|GEV825.89-1.53 (-0.18%) ▼|GILD156.61-0.58 (-0.37%) ▼|GM75.84-1.38 (-1.78%) ▼|GOOG319.00-1.76 (-0.55%) ▼|GOOGL322.04-2.18 (-0.67%) ▼|GS882.67-8.63 (-0.97%) ▼|HD318.43-9.30 (-2.84%) ▼|HON221.41+3.10 (+1.42%) ▲|IBM252.93+0.82 (+0.33%) ▲|INTC86.84+1.35 (+1.57%) ▲|INTU346.15-8.75 (-2.47%) ▼|ISRG453.48+9.63 (+2.17%) ▲|JNJ263.03-4.59 (-1.71%) ▼|JPM332.14-4.41 (-1.31%) ▼|KO92.81-2.54 (-2.66%) ▼|LIN508.28-2.08 (-0.41%) ▼|LLY1,264.74-41.96 (-3.21%) ▼|LMT606.54+16.63 (+2.82%) ▲|LOW198.74-5.63 (-2.75%) ▼|LRCX230.80+0.65 (+0.28%) ▲|MA622.06-11.15 (-1.76%) ▼|MCD247.61-5.02 (-1.99%) ▼|MDLZ63.54-1.65 (-2.53%) ▼|MDT95.87-0.72 (-0.75%) ▼|META644.58-4.28 (-0.66%) ▼|MMM173.96-1.61 (-0.91%) ▼|MO74.46-1.61 (-2.12%) ▼|MRK145.00-2.24 (-1.52%) ▼|MS180.85-3.12 (-1.70%) ▼|MSFT524.59+3.51 (+0.67%) ▲|MU883.15+26.66 (+3.11%) ▲|NEE81.71-0.19 (-0.23%) ▼|NFLX66.12-0.93 (-1.39%) ▼|NKE37.48-0.85 (-2.21%) ▼|NOW158.45+1.45 (+0.92%) ▲|NVDA211.67-0.54 (-0.25%) ▼|ORCL127.74+2.20 (+1.75%) ▲|PEP135.50-3.34 (-2.40%) ▼|PFE30.04-0.38 (-1.25%) ▼|PG161.31-3.19 (-1.94%) ▼|PLTR196.12-0.08 (-0.04%) ▼|PM199.53-2.21 (-1.10%) ▼|QCOM174.94+2.11 (+1.22%) ▲|RTX191.65-3.07 (-1.57%) ▼|SBUX100.70-1.21 (-1.19%) ▼|SCHW90.45-0.99 (-1.08%) ▼|SO92.91-0.92 (-0.98%) ▼|SPG210.98-1.06 (-0.50%) ▼|T21.23-1.52 (-6.66%) ▼|TMO670.40-6.14 (-0.91%) ▼|TMUS148.89-9.90 (-6.23%) ▼|TSLA372.06-2.52 (-0.67%) ▼|TXN284.60+5.10 (+1.82%) ▲|UBER67.21-1.87 (-2.70%) ▼|UNH417.92-7.07 (-1.66%) ▼|UNP294.02-4.07 (-1.37%) ▼|UPS101.29-0.23 (-0.23%) ▼|USB59.61-0.41 (-0.68%) ▼|V409.13-5.21 (-1.26%) ▼|VZ44.46-0.74 (-1.64%) ▼|WFC82.36-0.66 (-0.79%) ▼|WMT119.41-1.71 (-1.41%) ▼|XOM182.62+4.39 (+2.46%) ▲|
15.7 C
New York
Friday, October 23, 2026

Tag: signals

newsFORsourcecompanycontentinformation1releasesmarket

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026...

FLORENCE, Italy and NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal Phase 3 SENTRY trial will be presented as a late-breaking oral at The European Hematology Association (EHA) 2026 Congress.

Nalvurikenz Officially Launches Its Advanced AI Trading Platform for the Next Generation of Intelligent Investing in 2026

New York City, June 13, 2026 (GLOBE NEWSWIRE) --

In 2026, Nalvurikenz officially announced the release of its new AI-powered trading platform, integrating unique features and functionalities to simplify the trading process using a combination of artificial intelligence, live data analytics, and advanced automation.

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

Ripple’s XRP Meets AI Trading: AIXAlpha Launches Free AI Strategy Contracts with Daily Settlement

Join XRP and top assets through AI-driven automated strategies with daily settlement—no manual trading needed. 
Join XRP and top assets through AI-driven automated strategies with daily settlement—no manual trading needed.

SpaceX perpetual futures become Binance’s No. 2 traded product; Binance captures over 60% market share across CEX and DEX venues

Binance exceeded $5.6 billion in SPCXUSDT trading volume over last 24 hours, with over $9 billion in accumulated trading volume across SpaceX's Pre-IPO and...

EpiCooler Product Information Updated As Consumer Interest In Portable AC Grows In 2026

Kaunas, Lithuania, June 13, 2026 (GLOBE NEWSWIRE) --

An informational overview examining EpiCooler Portable AC Product Details, Publicly available product disclosures and what consumers often consider when researching portable cooling devices in 2026

HorseWood Claims Evaluated: The Horse Gelatin Trick for Natural Male Enhancement Support

Horsewood supplement evaluated: 7-herb botanical male vitality formula, NCCIH research context, and 60-day money-back guarantee.

Angle Advisors announces HBC Company has been acquired by GreenArrow, a portfolio company of CAI Capital Partners

Birmingham, MI, June 12, 2026 (GLOBE NEWSWIRE) -- Angle Advisors is pleased to announce that HBC Company, Inc. (“HBC”) has been acquired by GreenArrow, a portfolio company of CAI Capital Partners. Angle Advisors acted as the exclusive investment banking advisor to HBC in completing the transaction.

Roof Replacement Warning Signs Examined in HelloNation Featuring Roofing Expert Donovan Borntrager

The article explains how to identify early signs of roof damage and when homeowners should consider professional evaluation.BLOOMER, Wis., June 12, 2026 /PRNewswire/ --...

Morvulikent Officially Launches Its Advanced AI Trading Platform for the Next Generation of Automated Trading in 2026

New York City, June 12, 2026 (GLOBE NEWSWIRE) --

In 2026 Morvulikent has officially announced the launch of its new AI-powered trading platform, introducing a next-generation automated trading environment designed to simplify financial market participation through artificial intelligence, real-time data analysis, and intelligent automation.

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial

$300B in Year One: Versus Trade’s Growth Signals the Future of Retail Trading

Rodney Bay, Saint Lucia, June 11, 2026 (GLOBE NEWSWIRE) -- One year ago, Versus Trade entered the world's most competitive and crowded industries. Today, on its first anniversary, it has surpassed $300 billion in trading volume, doubling from $150 billion to $300 billion in a quarter and expanding its reach to traders across more than 45 countries.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSignals

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers